Trial record 36 of 225 for:
hyperbaric oxygen | Adult
Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05987852 |
|
Recruitment Status :
Recruiting
First Posted : August 14, 2023
Last Update Posted : April 15, 2024
|
Sponsor:
Northwestern University
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Lauren C Balmert, Northwestern University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Chronic intestinal hypoxia and accompanying mucosal inflammation is a hallmark of ulcerative colitis (UC). Hyperbaric oxygen therapy (HBOT) involves breathing 100% oxygen under increased atmospheric pressure to increase tissue oxygenation. Two small prospective randomized controlled trials have demonstrated that the delivery of HBOT to UC patients hospitalized for acute moderate to severe flares results in improved remission rates and avoidance of in-hospital progression to biologics, small molecules, or colectomy. In this larger trial the study aims to confirm the treatment benefits of HBOT for hospitalized UC patients and study the immune-microbe mechanisms underpinning treatment response.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Ulcerative Colitis | Device: Hyperbaric Oxygen Therapy Other: Sham Hyperbaric Air | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 126 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | 5-day intervention period; 12 months observational period through standard of care visits and follow-up |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Moderate to Severe Flares: A Multi-Center, Randomized, Double-Blind, Sham-Controlled Trial |
| Actual Study Start Date : | January 9, 2024 |
| Estimated Primary Completion Date : | September 1, 2027 |
| Estimated Study Completion Date : | September 1, 2027 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Ulcerative colitis
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Hyperbaric Oxygen Therapy
Participants enrolled in the active intervention group receiving HBOT will undergo compression to 2.4 Atmospheres Absolute (ATA; 100% O2) for 90 minutes with two 5-10 minute "air breaks" (breathing room air at the 2.4 ATA) during the session. This is done once a day for 5 days.
|
Device: Hyperbaric Oxygen Therapy
Participants enrolled in the active intervention group receiving HBOT will undergo compression to 2.4 Atmospheres Absolute (ATA; 100% O2) for 90 minutes with two 5-10 minute "air breaks" (breathing room air at the 2.4 ATA) during the session. This is done once a day for 5 days. |
|
Sham Comparator: Sham Hyperbaric Air
This control arm will undergo compression to 1.34 ATA for monoplace chambers and 2.4 ATA for multiplace chambers for the full 90-minute session but 21% oxygen instead of 100% oxygen being administered. These participants will also have two 5-10 minute "air breaks" to mimic the treatment protocol. Multiplace sham sessions will have modified air breaks to avoid decompression sickness. This will happen once a day for 5 days.
|
Other: Sham Hyperbaric Air
This control arm will undergo compression to 1.34 ATA for monoplace chambers and 2.4 ATA for multiplace chambers for the full 90-minute session but 21% oxygen instead of 100% oxygen being administered. These participants will also have two 5-10 minute "air breaks" to mimic the treatment protocol. Multiplace sham sessions will have modified air breaks to avoid decompression sickness. This will happen once a day for 5 days. |
Primary Outcome Measures :
- Clinical response defined as complete resolution of rectal bleeding and improvement in stool frequency, without need for in-hospital biologics, small molecules, or colectomy by study day 5 [ Time Frame: Day 5 ]Proportion of participants achieving clinical response as measured by complete resolution of rectal bleeding (Mayo rectal bleeding sub-score of 0) and improvement in stool frequency (at least 1 point reduction in Mayo stool frequency sub-score), without the need for in-hospital biologics, small molecules, or colectomy, by study day 5.
Secondary Outcome Measures :
- Endoscopic Improvement [ Time Frame: Day 5; Day 90 ]Proportion of participants achieving endoscopic improvement (Mayo endoscopic sub-score of 0 or 1)
- Endoscopic Remission [ Time Frame: Day 5; Day 90 ]Proportion of participants achieving Endoscopic remission (Mayo endoscopic sub-score of 0)
- Histologic Remission [ Time Frame: Day 5; Day 90 ]Proportion of participants achieving Histologic Remission (Geboes histology score ≤ 2)
- Mucosal Healing [ Time Frame: Day 5; Day 90 ]Proportion of participants achieving Mucosal Healing (Endoscopic sub-score 0 or 1 + Geboes histology score ≤ 2)
- Clinical Remission [ Time Frame: Day 3; Day 5; 12 months ]Proportion of participants achieving clinical remission (Full Mayo ≤ 2, with no sub-score > 1)
- Initiation and/or adjustment of biologics or small molecule inhibitors [ Time Frame: 12 months ]Proportion of participants who require initiation and/or adjustment in biologics or small molecule inhibitors, and number of biologics or small molecule inhibitors and/or adjustments required over 12 months
- Colectomy [ Time Frame: Day 5; 12 months ]Proportion of participants requiring colectomy
- Re-hospitalization [ Time Frame: 12 months ]Proportion of participants with any re-hospitalization during the follow-up period
- Serious Infections or Serious Adverse Events [ Time Frame: Day 5 ]Proportion of participants experiencing any serious infections or serious adverse events during intervention period
- Number of new initiations and/or adjustments in biologics or small molecule inhibitors [ Time Frame: 12 months ]Number of new initiations and/or adjustments in biologics or small molecule inhibitors
- Duration of index hospitalization [ Time Frame: From date of hospitalization to time of discharge, assessed up to 30 days ]Duration of index hospitalization
- Number of re-hospitalizations [ Time Frame: 12 months ]Number of re-hospitalizations
- Change in inflammation, as measured by C-reactive protein [ Time Frame: Day 3; Day 5 ]Change in inflammation, as measured by C-reactive protein
- Change in inflammation, as measured by fecal calprotectin [ Time Frame: Day 5 ]Change in inflammation, as measured by fecal calprotectin
- Full Mayo Score [ Time Frame: Day 5; Day 90 ]Score ranges from 0-12 ; higher scores are worse
- Ulcerative Colitis Endoscopic Index of Severity (UCEIS) [ Time Frame: Day 5; Day 90 ]Score ranges from 0-8 ; higher scores are worse
- Numeric Urgency Rating Score [ Time Frame: Day 3; Day 5 ]Score ranges from 0-10 ; higher scores are worse
- Improvement in individual Mayo sub-score for stool frequency [ Time Frame: Day 3; Day 5 ]Score ranges from 0-3 ; higher scores are worse ; improvement defined as decrease in score from baseline
- Improvement in individual Mayo sub-score for rectal bleeding [ Time Frame: Day 3; Day 5 ]Scores range from 0-3 ; higher scores are worse ; improvement defined as decrease in score from baseline
- Improvement in individual Mayo Endoscopic sub-score for mucosal appearance at endoscopy [ Time Frame: Day 5 ]Scores range from 0-3 ; higher scores are worse ; improvement defined as decrease in score from baseline
- Improvement in individual Mayo sub-score for physician rating of disease activity [ Time Frame: Day 3; Day 5 ]Scores range from 0-3 ; higher scores are worse ; improvement defined as decrease in score from baseline
- Improvement in urgency Simple Clinical Colitis Activity Index (SCCAI) sub-score [ Time Frame: Day 3; Day 5 ]Scores range from 0-3 ; higher scores are worse ; improvement defined as decrease in score from baseline
- Improvement in nocturnal bowel movement frequency Simple Clinical Colitis Activity Index (SCCAI) sub-score [ Time Frame: Day 3; Day 5 ]Scores range from 0-2 ; higher scores are worse ; improvement defined as decrease in score from baseline
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Participants with known or newly diagnosed UC who require hospitalization for an acute moderate to severe flare
- Age 18-85
- Consented and able to receive first HBOT session within first 48 hours of initiation of intravenous steroids
Exclusion Criteria:
- Complication requiring urgent surgical intervention
- Toxic megacolon
- Inability to receive intravenous steroids
- Historically failed 3 or more classes of advanced therapeutic options
- Known or suspected diagnosis of Crohn's colitis, indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, microscopic colitis or infectious colitis
- Received any investigational drug within 30 days
- Clinically significant cardiac, renal, neurological, endocrine, respiratory or hepatic impairment that increases the risk for HBOT toxicity
- Women who are pregnant or nursing
- Unwillingness to complete course of HBOT
- Active SARS CoV 2 infection
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05987852
Contacts
| Contact: Yasmin Pina, BS | 312-503-6459 | yasmin.pina@northwestern.edu | |
| Contact: Mary Beth Tull, MS | 312-503-4746 | mary.tull@northwestern.edu |
Locations
| United States, Alabama | |
| University of Alabama Medicine | Not yet recruiting |
| Birmingham, Alabama, United States, 35233 | |
| Contact: Kirk Russ, MD kruss@uabmc.edu | |
| United States, California | |
| University of Los Angeles Health | Recruiting |
| Los Angeles, California, United States, 90024 | |
| Contact: Jenny Sauk, MD jsauk@mednet.ucla.edu | |
| United States, Florida | |
| University of Miami Health | Not yet recruiting |
| Miami, Florida, United States, 33136 | |
| Contact: Oriana Damas, MD omazorra@med.miami.edu | |
| Orlando Health | Not yet recruiting |
| Orlando, Florida, United States, 32806 | |
| Contact: Udayakumar Navaneethan, MD udayakumar.navaneethan@orlandohealth.com | |
| United States, Illinois | |
| Northwestern Medicine Lake Forest Hospital | Recruiting |
| Lake Forest, Illinois, United States, 60045 | |
| Contact: Parambir S Dulai, MD parambir.dulai@northwestern.edu | |
| United States, Kentucky | |
| University of Louisville | Not yet recruiting |
| Louisville, Kentucky, United States, 40202 | |
| Contact: Gerald Dryden, MD tad.dryden@louisville.edu | |
| United States, Massachusetts | |
| Massachusetts General Hospital | Recruiting |
| Boston, Massachusetts, United States, 02114 | |
| Contact: Ashwin Ananthakrishnan, MD aananthakrishnan@mgh.harvard.edu | |
| United States, Minnesota | |
| Mayo Clinic | Recruiting |
| Rochester, Minnesota, United States, 55905 | |
| Contact: Laura Raffals, MD raffals.laura@mayo.edu | |
| United States, New Hampshire | |
| Dartmouth Hitchcock Medical Center | Recruiting |
| Lebanon, New Hampshire, United States, 03756 | |
| Contact: Corey Siegel, MD corey.a.siegel@hitchcock.org | |
| Contact: Michael Winter, MD michael.w.winter@hitchcock.org | |
| United States, New York | |
| Cornell University Medical Center | Recruiting |
| New York, New York, United States, 10065 | |
| Contact: Dana Lukin, MD djl9010@med.cornell.edu | |
| State University of New York Upstate Medical University | Recruiting |
| Syracuse, New York, United States, 13210 | |
| Contact: Marvin Heyboer, MD HeyboerM@upstate.edu | |
| United States, Oregon | |
| Oregon Health & Science University Health | Not yet recruiting |
| Portland, Oregon, United States, 97239 | |
| Contact: Anthony Sofia, MD sofia@ohsu.edu | |
| United States, Pennsylvania | |
| Allegheny Health | Recruiting |
| Pittsburgh, Pennsylvania, United States, 15090 | |
| Contact: Gursimran Kochhar, MD gursimran.kochhar@ahn.org | |
| University of Pittsburgh Medical Center | Recruiting |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| Contact: Jeffrey Dueker, MD duekerjm@upmc.edu | |
| United States, Virginia | |
| University of Virginia Health | Recruiting |
| Charlottesville, Virginia, United States, 22903 | |
| Contact: Anne Tuskey, MD agt2w@hscmail.mcc.virginia.edu | |
Sponsors and Collaborators
Northwestern University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
| Principal Investigator: | Lauren Balmert Bonner, PhD | Northwestern University |
| Responsible Party: | Lauren C Balmert, Professor, Northwestern University |
| ClinicalTrials.gov Identifier: | NCT05987852 |
| Other Study ID Numbers: |
HBOT-UC 1U01DK134321 ( U.S. NIH Grant/Contract ) |
| First Posted: | August 14, 2023 Key Record Dates |
| Last Update Posted: | April 15, 2024 |
| Last Verified: | April 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Dataset with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Repository. |
| Supporting Materials: |
Study Protocol Informed Consent Form (ICF) |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | Yes |
| Product Manufactured in and Exported from the U.S.: | Yes |
Keywords provided by Lauren C Balmert, Northwestern University:
|
hyperbaric oxygen therapy HBOT ulcerative colitis hyperbaric oxygen |
Additional relevant MeSH terms:
|
Colitis Colitis, Ulcerative Ulcer Gastroenteritis Gastrointestinal Diseases |
Digestive System Diseases Colonic Diseases Intestinal Diseases Pathologic Processes Inflammatory Bowel Diseases |